Literature DB >> 8316654

Early and late injuries in mouse rectum after fractionated X-ray and neutron irradiation.

A Gasinska1, B Dubray, S A Hill, J Denekamp, H D Thames, J F Fowler.   

Abstract

PURPOSE: to assess mouse rectum tolerance to fractionated X-ray and neutron irradiation.
MATERIALS AND METHODS: doses per fraction ranged between 0.25 and 35 Gy for X-rays, 0.05 and 12 Gy for neutrons. Neutron top-up doses were added when the fractionated irradiation was given in fractions less than 2 Gy of X-rays or 0.35 Gy of neutrons in order to bring the damage into the detectable range. The early endpoints were the nadir of weight loss occurring within the first 2-3 weeks following irradiation and lethality by 2 months. The late endpoints were the peak of weight reached at maturity of the mice, the proportion of short feces in the daily fecal output at 10 months and lethality by 12 months. The linear-quadratic (LQ) model was fitted to the data (direct "one-step" analysis) and the estimated parameters were used to calculate relative biological effectiveness (RBE) values.
RESULTS: alpha/beta ratio estimates were for X-rays: 19.9 Gy [95% confidence limits: 15.2, 27.0] for weight nadir. 13.4 Gy [9.3, 19.5] for early lethality, 6.4 Gy [3.6, 11.0] for peak weight, and 6.9 Gy [4.2, 10.8] for late lethality, for neutrons 19.9 Gy [9.5, 61.0] for peak weight. The fecal-deformity data were poorly fitted by the LQ model. The RBE was slightly higher for acute endpoints than for the late ones when X-ray fraction sizes were equal to or larger than 10 Gy. However, the change in RBE with decreasing X-ray dose per fraction was much steeper for the late endpoints, so that it became equal to or even higher than for acute reactions at doses per fraction of 5 Gy or less.
CONCLUSION: Our results were consistent with those obtained from previously published studies using the same experimental system but larger doses per fraction.

Entities:  

Mesh:

Year:  1993        PMID: 8316654     DOI: 10.1016/0167-8140(93)90266-b

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

Review 1.  Current status of intensity-modulated radiation therapy (IMRT).

Authors:  Kazuo Hatano; Hitoshi Araki; Mitsuhiro Sakai; Takashi Kodama; Naoki Tohyama; Tohru Kawachi; Masaharu Imazeki; Takayuki Shimizu; Tsutomu Iwase; Minoru Shinozuka; Hideyo Ishigaki
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

Review 2.  The contribution of women to radiobiology: Marie Curie and beyond.

Authors:  Anna Gasinska
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

3.  Estimation of α/β for late rectal toxicity based on RTOG 94-06.

Authors:  Susan L Tucker; Howard D Thames; Jeff M Michalski; Walter R Bosch; Radhe Mohan; Kathryn Winter; James D Cox; James A Purdy; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-04       Impact factor: 7.038

4.  Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.

Authors:  Alan Pollack; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Andre A Konski; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; C-M Charlie Ma; Shawn W McNeeley; Mark K Buyyounouski; Robert A Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

Review 5.  Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.

Authors:  Víctor Macías; Albert Biete
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

6.  Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results.

Authors:  Maurizio Valeriani; Alessia Carnevale; Mattia Falchetto Osti; Vitaliana DE Sanctis; Linda Agolli; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2014-09-26       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.